James Clavijo

James has over 25 years of experience in executive, finance and accounting activities, including experience as a Chief Financial Officer for several biotech, cell therapy, medical device, pharmaceutical, healthcare, and technology companies. 

Mr. Clavijo’s experience has included building, leading and advising companies with strategic plans for pharmaceutical commercialization and manufacturing, negotiating licensing and drug development agreements, as well as advising companies with complex restructurings, mergers and acquisitions, capital market transactions, and system implementations. From 2019-2021, Mr. Clavijo served as the Chief Financial Officer for Longeveron (NASDAQ:LGVN) a cell therapy company focused on the use of stem cells for various aging-related and life-threatening diseases.  Mr. Clavijo took Longeveron public through an IPO in February 2021. 

From 2016-2021, Mr. Clavijo served as the Consulting Chief Financial Officer for Guided Therapeutics (OTC: GTHP) an epithelial and cervical cancer medical device company.  During 2018, Mr. Clavijo served as the Chief Financial Officer for Aeterna Zentaris (NASDAQ: AEZS) a commercial stage biopharmaceutical company in growth hormone deficiency indications as well as other therapeutic assets